Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Other Operating Expenses (2021 - 2025)

Oncology Institute (TOI) has disclosed Other Operating Expenses for 5 consecutive years, with $118.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses rose 37.14% year-over-year to $118.4 million, compared with a TTM value of $395.8 million through Sep 2025, up 20.56%, and an annual FY2024 reading of $342.5 million, up 20.37% over the prior year.
  • Other Operating Expenses was $118.4 million for Q3 2025 at Oncology Institute, up from $103.1 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $118.4 million in Q3 2025 and bottomed at $39.0 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $70.2 million, with a median of $66.8 million recorded in 2023.
  • The sharpest move saw Other Operating Expenses dropped 0.03% in 2022, then soared 83.14% in 2023.
  • Year by year, Other Operating Expenses stood at $44.6 million in 2021, then soared by 48.94% to $66.5 million in 2022, then increased by 8.59% to $72.2 million in 2023, then rose by 19.71% to $86.4 million in 2024, then skyrocketed by 36.98% to $118.4 million in 2025.
  • Business Quant data shows Other Operating Expenses for TOI at $118.4 million in Q3 2025, $103.1 million in Q2 2025, and $87.9 million in Q1 2025.